panelarrow

An Inside Examination Of Strategies In Solar Generator System Vs Products Inc

solar generator system


The company is targeting adjusted earnings-per-share growth of 12% or more through 2020. It's planning to accomplish this goal in part by increasing sales of QuantiFERON-TB and by capturing at least 20% of the oncology benchtop sequencing market share for GeneReader NGS. Better buy I suspect that Qiagen might be able to deliver on its goals, which would likely push the stock higher. However, my vote between these two stocks goes to Opko. The 20% drop in Opko's value following the disappointing clinical results for hGH-CTP provides a good opportunity for a rebound. While there's definitely a risk that more bad news for the human growth hormone could weigh the stock down, I think the company has enough irons in the fire that something will serve as a positive catalyst this year to send shares higher. 10 stocks we like better than Opko Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Opko Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.


For the original version including any supplementary images or video, visit http://www.foxbusiness.com/markets/2017/01/18/better-buy-opko-health-inc-vs-qiagen.html


(visit site)


VS Products Inc

You may also be interested to read